Most Read Articles
13 Jul 2017

According to the Singapore National Registry of Diseases Office (NRDO), prostate cancer is the third most common cancer and the sixth most common cause of cancer-related deaths affecting men in Singapore. Dr Daniel Tan, radiation oncologist and medical director of Asian American Radiation Oncology at Gleneagles Hospital, Singapore, speaks to Roshini Claire Anthony on the importance of early detection of prostate cancer and the challenges associated with diagnosing and treating this condition. 

15 Oct 2017
Physiotherapy and behaviour therapy appear to be effective interventions in females with overactive bladder syndrome, with those who have had no previous exposure to the treatments benefitting from post-therapy effects, a recent study has shown.
Christina Lau, 20 Jan 2016
New data from the phase III METEOR trial (Metastatic Renal Cell Carcinoma Phase III Study Evaluating Cabozantinib vs Everolimus) provide compelling evidence for the efficacy of cabozantinib in patients with advanced clear-cell renal cell carcinoma (RCC) who progressed after first-line VEGF receptor-tyrosine kinase inhibitor (TKI) therapy.
22 May 2015
A highly selective M3 antagonist developed for treating overactive bladder (OAB).

Triptorelin better than surgical castration in lowering testosterone levels

20 May 2017
prostate cancer, Ejaculation frequency, prostate stagnation hypothesis

Compared with subcapsular orchiectomy, 24-week depot triptorelin injections significantly reduce testosterone levels, according to a Danish study.

“To our knowledge this is the first randomized study to demonstrate a difference in treatment effect between surgical and medical castration on testosterone levels,” researchers said.

A total of 58 consecutive hormone naïve men diagnosed with advanced prostate cancer from September 2013 to March 2015 were randomly assigned 1:1 to either subcapsular orchiectomy or triptorelin 22.5 mg given as 24-week depot injections. Follow-up was 48 weeks.

Liquid chromatography-tandem mass spectrometry was used to measure androgen status prior to treatment and after 12, 24, and 48 weeks. Longitudinal Tobit regression was used to analyse between-group differences in achieved hormone levels.

Patients treated with the luteinizing hormone-releasing hormone agonist triptorelin had 29-percent lower testosterone levels (95 percent CI, 17.2 to 41.7) compared to subcapsular orchiectomy (p<0.001). Compared to men undergoing orchiectomy, a significantly higher proportion of men receiving triptorelin had testosterone levels <20 ng/dl at weeks 12 (97 vs 79 percent) and 48 (100 vs 87 percent; p<0.05).

No detectable difference was observed in the adrenal androgen reduction between the two treatment groups.

“Recent evidence suggests that reaching the lowest achievable levels of testosterone with androgen deprivation therapy delays disease progression and increases overall survival in men with advanced prostate cancer,” according to researchers.

In a previous study, participants on luteinizing hormone-releasing hormone agonist therapy showed significantly lower testosterone levels than men who underwent surgical castration. All patients had serum testosterone values <50 ng/dl and 97 percent had testosterone concentrations <20 ng/dl. [J Urol 2012;187:1601-6]

Editor's Recommendations
Most Read Articles
13 Jul 2017

According to the Singapore National Registry of Diseases Office (NRDO), prostate cancer is the third most common cancer and the sixth most common cause of cancer-related deaths affecting men in Singapore. Dr Daniel Tan, radiation oncologist and medical director of Asian American Radiation Oncology at Gleneagles Hospital, Singapore, speaks to Roshini Claire Anthony on the importance of early detection of prostate cancer and the challenges associated with diagnosing and treating this condition. 

15 Oct 2017
Physiotherapy and behaviour therapy appear to be effective interventions in females with overactive bladder syndrome, with those who have had no previous exposure to the treatments benefitting from post-therapy effects, a recent study has shown.
Christina Lau, 20 Jan 2016
New data from the phase III METEOR trial (Metastatic Renal Cell Carcinoma Phase III Study Evaluating Cabozantinib vs Everolimus) provide compelling evidence for the efficacy of cabozantinib in patients with advanced clear-cell renal cell carcinoma (RCC) who progressed after first-line VEGF receptor-tyrosine kinase inhibitor (TKI) therapy.
22 May 2015
A highly selective M3 antagonist developed for treating overactive bladder (OAB).